Financial Data and Key Metrics Changes - Consolidated revenue for Q2 2023 was $541 million, with adjusted EBITDA of $44 million, exceeding the high end of guidance ranges [5][41] - Gross profit was $123 million, representing a gross margin of 22.8%, which was up 40 basis points sequentially [17] - Adjusted earnings per share was $0.69, above the high end of guidance, driven by strong performance and lower interest expense [20] Business Line Data and Key Metrics Changes - Travel business revenue decreased approximately 16% sequentially and 36% year-over-year, with average bill rates down 7% sequentially [6][72] - Physician staffing revenue increased 105% year-over-year, now on an annual revenue run rate of over $180 million [8] - Education division grew 42% year-over-year, nearing an annual revenue run rate of $100 million [8] Market Data and Key Metrics Changes - Home care staffing services revenue was down 2% year-over-year, primarily due to lower needs from a single client [22] - The overall demand for travel nurses has shown signs of gradual improvement, although the growth in the number of travelers has been slower than anticipated [31][73] Company Strategy and Development Direction - The company is focused on leveraging technology investments, particularly through the Intellify platform, to enhance operational efficiency and client service [12][33] - The strategy includes diversifying the platform and entering new markets, as evidenced by the recent acquisition and expansion into interim leadership [38] - The company aims to maintain profitability while investing in high-growth potential areas and technology initiatives [18] Management's Comments on Operating Environment and Future Outlook - Management noted that while demand has softened, there are signs of recovery, particularly in specific medical specialties [31] - The outlook for Q3 2023 anticipates revenue between $440 million and $450 million, reflecting a sequential decline due to travel bill rate pressures and seasonal impacts [37][76] - Management expressed confidence in the long-term growth potential, particularly with the expected stabilization of bill rates and increasing demand [60][127] Other Important Information - The company repaid the remaining $74 million on its term loan in June and restored a $100 million share repurchase plan [13][23] - Cash generated from operations was $119 million, the second highest quarter on record, indicating strong cash flow management [75] Q&A Session All Questions and Answers Question: What is the outlook for the relationship with MSPs moving forward? - Management indicated that MSPs remain vital to the strategy, but there is a shift towards vendor-neutral models in the marketplace [50][52] Question: Can you provide clarity on demand trend visibility given the revenue guidance adjustments? - Management acknowledged the challenges but emphasized that they are trying to provide the most accurate guidance based on current data [57][58] Question: How do you anticipate seasonal orders will play out? - Management noted that clients are looking to secure longer contracts to prepare for flu season, but visibility into the volume of orders is still developing [64][66] Question: What is the impact of MSP churn on the business? - Management confirmed that there has been higher churn than historically seen, primarily towards vendor-neutral players, but they are well-positioned to capture market share [89][92] Question: How is the company managing the gap between order rates and nurse compensation expectations? - Management highlighted that there is a disparity between current bill rates and nurse pay expectations, which they believe will reach equilibrium in the coming months [60][84]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ——————— FORM 10-Q ——————— ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From _________ to _________ ——————— CROSS COUNTRY HEALTHCARE, INC. (Exact name of registrant as specified in its charter) ——————— Delaware 0-33169 13-4066229 (St ...

Cross Country Healthcare, Inc. (NASDAQ:CCRN) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Josh Vogel - Vice President, Investor Relations John Martins - President and Chief Executive Officer Bill Burns - Chief Financial Officer Dan White - Chief Commercial Officer Marc Krug - Group President, Delivery Conference Call Participants Kevin Fischbeck - Bank of America A.J. Rice - Credit Suisse Tobey Sommer - Truist Securities Bill Sutherland - The Benchmark Company Operator Good a ...

Revenue Performance - Revenue from services decreased by 21.0% to $622.7 million for the three months ended March 31, 2023, compared to $788.7 million for the same period in 2022[15] - Contribution income decreased by 39.0% to $67.2 million for the three months ended March 31, 2023, compared to $110.1 million for the same period in 2022[34] - The average Nurse and Allied Staffing revenue per FTE per day decreased by 18.3% to $513 for the three months ended March 31, 2023[28] Net Income and Expenses - Net income attributable to common stockholders was $29.4 million for the three months ended March 31, 2023, down 52.5% from $62.0 million in the same period in 2022[15] - Bad debt expense increased to $4.9 million, representing 0.8% of revenue for the three months ended March 31, 2023, compared to 0.3% in the prior year[24] - Corporate overhead increased to $18.7 million for the three months ended March 31, 2023, from $16.3 million in the prior year, representing 3.0% of consolidated revenue[31] Cash Flow and Financing Activities - Cash flow provided by operating activities was $46.9 million, with net repayments of $10.4 million on the senior secured asset-based credit facility as of March 31, 2023[13] - For the three months ended March 31, 2023, net cash used in financing activities was $46.7 million, compared to $31.3 million provided by financing activities in the same period of 2022[46] - The company reported $0.3 million in cash and cash equivalents and $73.9 million of term loan outstanding as of March 31, 2023[32] Debt and Loan Agreements - The company entered into a Term Loan Agreement on June 8, 2021, for a total of $100.0 million with an interest rate of one-month LIBOR plus 5.75% per annum, subject to a 0.75% LIBOR floor[39] - The company amended the Term Loan Agreement on November 18, 2021, to include an incremental term loan of $75.0 million, primarily to fund organic growth[41] - The company made optional prepayments totaling $100.0 million on the term loan in 2022, incurring prepayment premiums of $1.0 million and writing off debt issuance costs of $2.7 million[43] Compliance and Financial Ratios - As of March 31, 2023, the company was in compliance with the minimum net leverage ratio covenant under the Term Loan Agreement[40] - As of March 31, 2023, the company had $300.0 million available under the ABL, with $66.4 million drawn and $18.2 million in letters of credit outstanding, leaving $215.4 million of excess availability[49] Other Financial Metrics - Days sales outstanding (DSO) increased by 8 days year-over-year to 70 days as of March 31, 2023[32] - A 1% change in interest rates would have resulted in interest expense fluctuations of approximately $0.4 million for the three months ended March 31, 2023[63] - The company repurchased 1,223,404 shares of common stock for $31.7 million during the first quarter of 2023, with $44.5 million remaining for share repurchase under the New Repurchase Program[37]

Financial Data and Key Metrics Changes - Consolidated revenue for Q4 2022 was $620 million, approximately 5% above the upper end of guidance, while adjusted EBITDA was $57 million, representing a 9.1% margin [7][20][40] - Total selling, general and administrative (SG&A) expenses were $81 million, up 1% sequentially and 23% year-over-year, with SG&A as a percentage of revenue at 12.9%, an increase of over 250 basis points from the prior year [10][21] - Adjusted earnings per share for the quarter was $1.09, up slightly over the third quarter and well above the upper end of guidance [21] Business Line Data and Key Metrics Changes - Nurse and Allied reported revenue of $591 million, a decline of 5% year-over-year and 3% sequentially, primarily due to a 3% drop in average bill rates and a 2% decrease in volume [11][22] - The local business experienced a slight sequential decline, while other lines such as locums, education, and homecare showed growth, with locums up nearly 8% sequentially [18][22] - Physician staffing revenue was $37 million, representing an 84% increase year-over-year and 56% sequentially, with organic growth of 28% excluding acquisitions [46] Market Data and Key Metrics Changes - More than 50% of revenue comes from Managed Service Providers (MSPs), with approximately 15% of total spend under management migrated to the Intellify platform as of December [8][19] - The company noted a higher than normal level of client attrition but stated that the pipeline for new opportunities has never been stronger [8][19] - The market for staffing is projected at $50 billion, with 40% being MSP, 40% vendor-neutral, and 20% direct clients [82] Company Strategy and Development Direction - The company is focused on expanding its digital transformation and enhancing its technology offerings, including the launch of Intellify and Gateway [16][40] - Strategic investments are being made in technology initiatives, personnel, and tuck-in acquisitions to bolster and diversify the portfolio [17][40] - The company aims to maintain a high single-digit to low double-digit EBITDA margin while growing higher-margin businesses [80] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing a strong pipeline and the ability to adapt to changing market conditions [8][19] - The company anticipates continued pressure on orders and bill rates but believes that the persistent labor shortage will sustain demand [41][42] - For Q1 2023, revenue is expected to be between $590 million and $600 million, with adjusted EBITDA between $44 million and $49 million [48] Other Important Information - The company repurchased 1.4 million shares, or roughly 4% of outstanding shares, as part of a $100 million share repurchase program [17][24] - The company ended the quarter with $4 million in cash and $151 million in outstanding debt, maintaining a low leverage ratio of less than 0.5x [23] Q&A Session Summary Question: What is the expectation for bill rates and how will the company adjust infrastructure? - Management indicated that bill rates are expected to normalize and that they utilize sophisticated capacity modeling to adjust resources as needed [26][27] Question: What would prompt a larger adjustment to infrastructure? - Management noted that natural attrition and capacity metrics would guide decisions on backfilling roles, allowing for adjustments without overreacting [36][60] Question: How is the company addressing client attrition and competition in the market? - Management highlighted that while there has been client attrition, the company has a strong pipeline and is well-positioned to win new business as contracts come up for bid [78][82]

Financial Performance - For the year ended December 31, 2022, total revenue increased by 67% year-over-year to $2.8 billion, driven by strong performance in both Nurse and Allied Staffing and Physician Staffing segments[162]. - Nurse and Allied Staffing represented approximately 96% of total revenue for the year ended December 31, 2022, with revenue from this segment reaching $2.7 billion, an increase of 68.2% from $1.6 billion in 2021[161][179]. - Net income attributable to common stockholders for the year ended December 31, 2022, was $188.5 million, compared to $132.0 million in 2021, reflecting a year-over-year increase of 42.7%[162]. - Contribution income for the year ended December 31, 2022, increased by $149.7 million or 72.8% to $355.4 million, with a contribution income margin of 13.2%[224]. Cash Flow and Expenses - Cash flow provided by operating activities was $134.1 million for the year ended December 31, 2022, compared to a cash outflow of $85.6 million in 2021, indicating a significant improvement in operational cash flow[184]. - Direct operating expenses increased by 67.4% to $2.2 billion for the year ended December 31, 2022, as a result of revenue increases, maintaining a consistent percentage of total revenue at 77.6%[168]. - Selling, general and administrative expenses rose by 50.6% to $324.2 million for the year ended December 31, 2022, but decreased as a percentage of total revenue to 11.6% from 12.8% in 2021[169]. - Corporate overhead increased to $67.1 million for the year ended December 31, 2022, but decreased as a percentage of consolidated revenue to 2.4% from 3.3% in 2021[181]. - Income tax expense for the year ended December 31, 2022, totaled $67.9 million, up from $1.2 million in 2021, with an effective tax rate of 26.5% compared to 1.0% in 2021[196]. Staffing and Workforce - The average number of FTEs in Nurse and Allied Staffing increased by 49.6% to 12,980 in 2022, driven by headcount growth and the WSG acquisition[198][200]. - Average revenue per FTE per day in Nurse and Allied Staffing rose by 12.3% to $565 in 2022, reflecting increased travel bill rates[198][200]. - Total days filled in Physician Staffing increased by 35.9% to 60,038 in 2022, with revenue per day filled at $1,769, up 10.2% from $1,605 in 2021[198][225]. - The healthcare workforce shortage has been exacerbated by the pandemic, but the company has successfully hired and retained healthcare professionals due to its strong culture and operational performance[266]. Investments and Acquisitions - The company made optional prepayments on its term loan totaling $100 million in 2022 to reduce interest costs[163]. - The company entered into asset purchase agreements in 2022 to expand its locum tenens portfolio and strengthen its position in talent management[163]. - The company acquired HireUp Leadership Inc. in December 2022, enhancing its ability to recruit healthcare leaders across various specialties[262]. - The company’s acquisitions in 2022 and 2021 are part of its strategy to expand its service offerings and support critical healthcare needs[262]. Technology and Operations - The proprietary vendor management system, Intellify, is expected to be fully deployed by 2024, enhancing customer visibility and management of spend[264]. - The company has improved its applicant tracking system and on-demand staffing platform, leading to increased efficiency and candidate conversion ratios[264]. - The healthcare staffing industry is increasingly relying on technology, with over 66% of health systems and hospitals using automation tools for revenue cycle operations[263]. - The company continues to modernize its technologies and processes to optimize relationships with healthcare professionals and customers[265]. Financial Position and Capital Management - Working capital increased by $95.5 million to $404.0 million as of December 31, 2022, compared to $308.5 million in 2021, primarily due to an increase in accounts receivable[202]. - Net cash used in financing activities for the year ended December 31, 2022, was $87.6 million, compared to net cash provided of $119.1 million in 2021[204]. - Net cash used in investing activities for the year ended December 31, 2022, was $43.9 million, an increase from $34.0 million in 2021, primarily due to acquisitions of Mint and HireUp totaling $35.1 million[228]. - The company authorized a new repurchase program for up to $100.0 million of its common stock in the third quarter of 2022[227]. Compliance and Risk Management - The company was in compliance with its minimum net leverage ratio covenant as of December 31, 2022[229]. - The company maintains various insurance policies to cover potential liabilities arising from its operations[271]. - As of December 31, 2022, total unrecognized tax benefits recorded was $7.6 million[223]. - The company recorded a valuation allowance release of $37.5 million for deferred tax assets in 2021, indicating improved realizability of these assets[252]. Community and Employee Engagement - The company believes that taking care of its people and communities will lead to overall success, a mindset that has resonated with employees and customers[266]. - The company offers competitive compensation and benefits, including professional liability insurance, a 401(k) plan, health insurance, and reimbursed travel[268]. - The number of students receiving special education services was 7.2 million, or 15% of all public school students, highlighting the increased need for healthcare services in schools[274]. - The company is positioned to assist healthcare systems in managing costs through vendor-neutral and tech-enabled platforms, such as Intellify[275].

Cross Country Healthcare, Inc. (NASDAQ:CCRN) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Josh Vogel - VP, IR John Martins - President and CEO Bill Burns - EVP and CFO Marc Krug - Group President, Delivery Daniel White - CCO Conference Call Participants Kevin Fischbeck - Bank of America A.J. Rice - Credit Suisse Brian Tanquilut - Jefferies Tobey Sommer - Truist Securities Kevin Steinke - Barrington Research Good afternoon, everyone. Welcome to the Cross Country Healthcar ...

PART I. – FINANCIAL INFORMATION [Item 1. Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) This section provides Cross Country Healthcare's unaudited condensed consolidated financial statements for the periods ended September 30, 2022 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20%28Unaudited%29) Total assets increased to $882.5 million, with stockholders' equity growing to $422.7 million, driven by strong net income Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $30,320 | $1,036 | | Accounts receivable, net | $610,897 | $493,910 | | Total current assets | $660,017 | $508,273 | | Total assets | $882,512 | $732,809 | | **Liabilities & Equity** | | | | Total current liabilities | $276,790 | $199,770 | | Long-term debt, less current portion | $129,755 | $176,366 | | Total liabilities | $459,803 | $435,281 | | Total stockholders' equity | $422,709 | $297,528 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20%28Unaudited%29) Q3 2022 revenue increased 69.7% to $636.1 million, with nine-month revenue growing 110.3% to $2.18 billion Q3 2022 vs Q3 2021 Performance (in thousands, except per share data) | Metric | Q3 2022 | Q3 2021 | | :--- | :--- | :--- | | Revenue from services | $636,098 | $374,905 | | Income from operations | $52,175 | $26,447 | | Net income | $34,793 | $23,433 | | Diluted EPS | $0.93 | $0.62 | Nine Months 2022 vs 2021 Performance (in thousands, except per share data) | Metric | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | | Revenue from services | $2,178,391 | $1,035,973 | | Income from operations | $221,644 | $63,342 | | Net income | $149,670 | $54,429 | | Diluted EPS | $3.97 | $1.46 | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity%20%28Unaudited%29) Stockholders' equity increased to $422.7 million, driven by $149.7 million in net income, partially offset by stock repurchases - During the third quarter of 2022, the company repurchased and retired **1,014,815 shares** of common stock for **$24.3 million**[12](index=12&type=chunk)[16](index=16&type=chunk)[91](index=91&type=chunk) - Retained earnings improved from a deficit of **$(22.7) million** at the end of 2021 to a positive balance of **$126.9 million** as of September 30, 2022, due to strong profitability[16](index=16&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20%28Unaudited%29) Nine-month operating cash flow was $129.7 million, a significant improvement, with $93.7 million used in financing activities Cash Flow Summary - Nine Months Ended Sep 30 (in thousands) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $129,730 | $(12,253) | | Net cash used in investing activities | $(6,763) | $(29,360) | | Net cash (used in) provided by financing activities | $(93,674) | $40,869 | | **Change in cash and cash equivalents** | **$29,284** | **$(758)** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements%20%28Unaudited%29) The notes provide detailed explanations of accounting policies, significant transactions, and financial statement line items - On October 3, 2022, after the reporting period, the company acquired **Mint Medical Physician Staffing, LP** and **Lotus Medical Staffing LLC**[117](index=117&type=chunk) - In Q3 2022, the company paid a **$7.5 million** earnout for the WSG acquisition; in Q2 2022, the earnout liability for the Selected acquisition was reversed[43](index=43&type=chunk)[38](index=38&type=chunk)[87](index=87&type=chunk) - On August 16, 2022, the Board authorized a new stock repurchase program for up to **$100.0 million**; as of September 30, 2022, **$87.2 million** remained available[91](index=91&type=chunk)[92](index=92&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q3 2022 financial performance, including revenue growth, segment results, liquidity, and capital resources - Q3 2022 revenue increased **70% year-over-year** to **$636.1 million**, driven by an increase in professionals on assignment and volume growth[126](index=126&type=chunk) - The company anticipates a **high single-digit sequential decline** in average travel bill rates for the remainder of 2022[127](index=127&type=chunk) - A new stock repurchase program of up to **$100.0 million** was authorized in Q3 2022, with **$24.3 million** worth of stock repurchased during the quarter[130](index=130&type=chunk) [Results of Operations](index=31&type=section&id=Results%20of%20Operations) Q3 2022 revenue grew 69.7% to $636.1 million, with nine-month revenue increasing 110.3% to $2.2 billion Comparison of Three Months Ended September 30 (in thousands) | Line Item | 2022 | 2021 | % Change | | :--- | :--- | :--- | :--- | | Revenue from services | $636,098 | $374,905 | 69.7% | | Income from operations | $52,175 | $26,447 | 97.3% | | Net income | $34,793 | $23,433 | 48.5% | Comparison of Nine Months Ended September 30 (in thousands) | Line Item | 2022 | 2021 | % Change | | :--- | :--- | :--- | :--- | | Revenue from services | $2,178,391 | $1,035,973 | 110.3% | | Income from operations | $221,644 | $63,342 | 249.9% | | Net income | $149,670 | $54,429 | 175.0% | [Segment Results](index=36&type=section&id=Segment%20Results) Nurse and Allied Staffing revenue grew 71.9% to $612.3 million, driven by increased FTEs and higher revenue per FTE Nurse and Allied Staffing Performance - Q3 2022 vs Q3 2021 | Metric | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $612.3M | $356.1M | 71.9% | | Contribution Income | $77.8M | $40.6M | 91.5% | | FTEs | 12,524 | 9,003 | 39.1% | | Avg. Revenue per FTE per day | $526 | $425 | 23.8% | Physician Staffing Performance - Q3 2022 vs Q3 2021 | Metric | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $23.8M | $18.8M | 27.0% | | Days filled | 13,219 | 12,187 | 8.5% | | Revenue per day filled | $1,803 | $1,540 | 17.1% | [Liquidity and Capital Resources](index=38&type=section&id=Liquidity%20and%20Capital%20Resources) The company reported $30.3 million in cash, $129.7 million in nine-month operating cash flow, and $273.3 million ABL availability - Net cash provided by operating activities was **$129.7 million** in the first nine months of 2022, compared to **$12.3 million used** in the same period of 2021, primarily due to strong collections[185](index=185&type=chunk) - Financing activities in the first nine months of 2022 used **$93.7 million**, including **$50.4 million** in term loan repayments, a **$7.5 million** contingent consideration payment, and **$24.3 million** for stock repurchases[186](index=186&type=chunk) - The company had **$273.3 million** of excess availability under its **$300.0 million ABL facility** as of September 30, 2022[194](index=194&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is variable interest rates on its Term Loan and ABL facility, with no material changes since 2021 - A hypothetical **1% change in interest rates** would have impacted interest expense by approximately **$1.2 million** for the nine months ended September 30, 2022[202](index=202&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective, with no material changes to internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures are effective[205](index=205&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[206](index=206&type=chunk) PART II. – OTHER INFORMATION [Legal Proceedings](index=42&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various ordinary course legal proceedings, with management expecting no material adverse effect on its financials - The company is involved in various legal proceedings related to employee matters, professional liability, and tax practices, which are considered part of the ordinary course of business[105](index=105&type=chunk) - Management does not expect the outcome of any outstanding legal matters as of September 30, 2022, to have a material adverse effect on the business[105](index=105&type=chunk)[209](index=209&type=chunk) [Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the company's risk factors were reported compared to the 2021 Annual Report on Form 10-K - No material changes to risk factors were reported compared to the 2021 Form 10-K[210](index=210&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including CEO and CFO certifications and XBRL data files - Exhibits filed include certifications from the CEO and CFO under Rule 13a-14(a) and Section 1350, as well as XBRL interactive data files[212](index=212&type=chunk) Signatures - The report was signed on **November 3, 2022**, by **William J. Burns**, Executive Vice President & Chief Financial Officer[217](index=217&type=chunk)

Q2 2022 Investor Relations September 2022 Forward Looking Statements This presentation contains forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", "appears","seeks", "will" and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncert ...

Cross Country Healthcare, Inc. (NASDAQ:CCRN) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Josh Vogel - Vice President, Investor Relations John A. Martins - President and Chief Executive Officer William J. Burns - Executive Vice President and Chief Financial Officer Daniel J. White - Chief Commercial Officer Conference Call Participants Kevin Fischbeck - Bank of America Taji Phillips - Jefferies Financial Group Inc. Tobey Sommer - Truist Securities William Sutherland - The ...